» Articles » PMID: 31428232

An Update on Novel Therapeutic Warfronts of Extracellular Vesicles (EVs) in Cancer Treatment: Where We Are Standing Right Now and Where to Go in the Future

Overview
Publisher Wiley
Date 2019 Aug 21
PMID 31428232
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Extracellular vesicles (EVs) are a heterogeneous group of membrane-bounded vesicles that are believed to be produced and secreted by presumably all cell types under physiological and pathological conditions, including tumors. EVs are very important vehicles in intercellular communications for both shorter and longer distances and are able to deliver a wide range of cargos including proteins, lipids, and various species of nucleic acids effectively. EVs have been emerging as a novel biotherapeutic platform to efficiently deliver therapeutic cargos to treat a broad range of diseases including cancer. This vast potential of drug delivery lies in their abilities to carry a variety of cargos and their ease in crossing the biological membranes. Similarly, their presence in a variety of body fluids makes them a potential biomarker for early diagnosis, prognostication, and surveillance of cancer. Here, we discuss the relatively least and understudied aspects of EV biology and tried to highlight the obstacles and limitations in their clinical applications and also described most of the new warfronts to beat cancer at multiple stages. However, much more challenges still remain to evaluate EV-based therapeutics, and we are very much hopeful that the current work prompts further discovery.

Citing Articles

Surface-Engineered Extracellular Vesicles in Cancer Immunotherapy.

Johnson V, Vasu S, Kumar U, Kumar M Cancers (Basel). 2023; 15(10).

PMID: 37345176 PMC: 10216164. DOI: 10.3390/cancers15102838.


Tumor-derived extracellular vesicles modulate innate immune responses to affect tumor progression.

Wang S, Sun J, Dastgheyb R, Li Z Front Immunol. 2022; 13:1045624.

PMID: 36405712 PMC: 9667034. DOI: 10.3389/fimmu.2022.1045624.


Bioactivity of Exosomes Derived from Trained Natural Killer Cells versus Non-Trained One: More Functional and Antitumor Activity.

Mohammadi F, Hashemi Z, Sarrami Forooshani R, Alizadeh S Biomed Res Int. 2022; 2022:5396628.

PMID: 36060136 PMC: 9433262. DOI: 10.1155/2022/5396628.


Pioneer Role of Extracellular Vesicles as Modulators of Cancer Initiation in Progression, Drug Therapy, and Vaccine Prospects.

Jahan S, Mukherjee S, Ali S, Bhardwaj U, Choudhary R, Balakrishnan S Cells. 2022; 11(3).

PMID: 35159299 PMC: 8833976. DOI: 10.3390/cells11030490.


The mini player with diverse functions: extracellular vesicles in cell biology, disease, and therapeutics.

Thakur A, Ke X, Chen Y, Motallebnejad P, Zhang K, Lian Q Protein Cell. 2021; 13(9):631-654.

PMID: 34374936 PMC: 9233731. DOI: 10.1007/s13238-021-00863-6.


References
1.
Maas S, Breakefield X, Weaver A . Extracellular Vesicles: Unique Intercellular Delivery Vehicles. Trends Cell Biol. 2016; 27(3):172-188. PMC: 5318253. DOI: 10.1016/j.tcb.2016.11.003. View

2.
Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

3.
Yang Q, Diamond M, Al-Hendy A . The emerging role of extracellular vesicle-derived miRNAs: implication in cancer progression and stem cell related diseases. J Clin Epigenet. 2016; 2(1). PMC: 4834835. View

4.
Nair R, Santos L, Awasthi S, von Erlach T, Chow L, Bertazzo S . Extracellular vesicles derived from preosteoblasts influence embryonic stem cell differentiation. Stem Cells Dev. 2014; 23(14):1625-35. DOI: 10.1089/scd.2013.0633. View

5.
Sedgwick A, DSouza-Schorey C . The biology of extracellular microvesicles. Traffic. 2018; 19(5):319-327. PMC: 6922305. DOI: 10.1111/tra.12558. View